Business Wire

Carbon Trade eXchange (CTX) Launches ITMO Carbon Auction: Investors Can Now Enter Most Important Carbon Market on Earth

3.7.2024 20:47:00 EEST | Business Wire | Press release

Share

The long awaited ITMO Auction is ready to take buyer Registration via the world´s first and leading global Voluntary Carbon platform, Carbon Trade Exchange (CTX). Carbon market brokers, investors plus new players like family offices or funds can participate.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240703957790/en/

Malawi Vice President Honorable Michael Usi with Gold Standard CEO Margaret Kim at COP28 Dubai (Photo: Business Wire)

The Auction will commence on Tuesday 16thJuly to finish on Tuesday 23rd July2024, hosted at https://ctxglobal.com/auctions/. Auction starting price is $10 USD per credit, with minimum starting bid of only $250,000.

Featuring 1.5 million issued credits forsale, already escrowed in CTX’s Gold Standard Registry account, triggers much needed climate finance, benefiting people across Malawi. ITMO prices are forecast by many exerts to be $100+ by 2030.

The Dual Certified project (Gold Standard and UNFCCC CDM) has Malawi Government Letter of Authorisation under Article 6 - Malawi support this Auction. “We want the carbon market to boost the country’s economy, create jobs and real benefits in our towns and villages and so we look forward to a successful auction and hope this can be the first of many,” says Malawi’s Vice President and Minister of Natural Resources and Climate Change, Honourable Michael Usi.

Over 550,000 households benefit from this High Quality Gold Standard project which disseminates the “Chitetezo Mbaula” cleaner cook stove, designed, developed and produced in Malawi: tackling 7 Sustainable Development Goals (SDGs). The Stove reduces 46% in-home particles and carbon monoxide by 44%, and decreases firewood consumption by 40%, combating deforestation. By lowering emissions by 2 tCO2e annually per family – Carbon Credits can finance the project.

Final bid credits can be immediately transferred to any GS Registry account or held under escrow by CTX for future resale or cancellation – Voluntary or Nations or CORSIA.

“Finding High Quality ITMOs since we launched the Auction concept at COP28, has been like digging for gold,” says CTX CEO, Wayne Sharpe. “We found the richest vein we could hope for, in our long-standing partners, Gold Standard, and a well-established CTX client. Putting funds into Cookstoves in Malawi ticks every box we ever created CTX for in the first place.”

Gold Standard CEO, Margaret Kim added, “Projects like this one, funded by the purchase of carbon credits, make a real difference to the planet and to people’s health and livelihoods.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20240703957790/en/

Contacts

Wayne Sharpe
auctions@ctxglobal.com
+44 20 3598 5890

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ryan Expands UK Business Rates and Property Tax Capabilities with Acquisition of WYM Rating5.2.2026 10:00:00 EET | Press release

Ryan, a leading global tax services and software provider, is pleased to announce the acquisition of Williams Young McKaig Ltd, a specialized commercial property consultancy, and its specialist rating division, WYM Rating, based in Edinburgh. The acquisition establishes Ryan’s property tax and business rates presence in Scotland and expands the Firm’s ability to serve clients with complex commercial property portfolios across the United Kingdom. Founded in 2012 by Richard Williams, Don Young, and Billy McKaig, WYM Rating is recognized for its client-centered approach and deep expertise across commercial property advisory. The consultancy supports landlords, occupiers, and investors through practical, market-informed advice grounded in decades of hands-on experience. WYM Rating’s capabilities span three focus areas, closely aligning with Ryan’s capabilities: Business rates and property tax Commercial property advisory Occupier and lease advisory “WYM Rating brings exactly the kind of sp

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 08:30:00 EET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release

VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye